stella
Prostate CancerMarch 2025Summary reviewed October 2026

Adding 6 Months of Hormone Therapy Doubled Time Before Prostate Cancer Spread

Men with recurring prostate cancer who got targeted radiation plus six months of hormone therapy stayed disease-free for 32 months — more than twice as long as those who got radiation alone. The combination delayed the need for long-term hormone treatment without serious side effects.

What the trial was testing

The RADIOSA enrolled 80 patients with prostate cancer. The study was sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

Radiation plus short-term hormone therapy doubled the time before cancer progressed compared to radiation alone.

The Lancet. Oncology · 2025 · NCT02680587

These findings — that time before cancer progressed with combination treatment versus radiation alone — were published in the The Lancet. Oncology and represent the headline result of the study.

Researchers tracked outcomes across 80 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with prostate cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

If your prostate cancer has come back in a few spots after initial treatment, this combination approach might buy you significantly more time before needing stronger treatments. The hormone therapy is temporary — just six months — and most side effects resolved after treatment ended. Both radiation and hormone therapy are FDA-approved for prostate cancer. Talk to your oncologist about whether this strategy fits your situation.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.